˵ڡ2019910µѪҺо¹ڿ塱
һ·ı
20199µ20203֮ȡ959λ˵Ѫڰ֢⡣202011¼ʱ֣11.6%Ѫ¹ڿ壨Their findings released in November showed 11.6% of 959 healthy volunteers enrolled in the cancer screening trial between September 2019 and March 2020 had signs of having already encountered SARS-CoV-2, most of them well before February
Ǻ˹ķ˹ѧѧ˵ǶıȷЩԱ棬ˣвͬĽ"Based on the criteria that we set, we could not confirm the majority of positives. Therefore, we had a different conclusion," said Marion Koopmans at Erasmus University
˹ķ˹ѧıҪ(IgM,IgCͿԻ⣬ȫԣ
But Erasmus' criteria required all three coronavirus-linked antibodies - IgM, neutralising antibodies and IgG - to be identified, and none of the samples fulfilled that requirement
https://www.reuters.com/world/europe/dispute-over-italian-coronavirus-study-shows-challenges-probing-origins-2021-07-23/
һ·ı
20199µ20203֮ȡ959λ˵Ѫڰ֢⡣202011¼ʱ֣11.6%Ѫ¹ڿ壨Their findings released in November showed 11.6% of 959 healthy volunteers enrolled in the cancer screening trial between September 2019 and March 2020 had signs of having already encountered SARS-CoV-2, most of them well before February
Ǻ˹ķ˹ѧѧ˵ǶıȷЩԱ棬ˣвͬĽ"Based on the criteria that we set, we could not confirm the majority of positives. Therefore, we had a different conclusion," said Marion Koopmans at Erasmus University
˹ķ˹ѧıҪ(IgM,IgCͿԻ⣬ȫԣ
But Erasmus' criteria required all three coronavirus-linked antibodies - IgM, neutralising antibodies and IgG - to be identified, and none of the samples fulfilled that requirement
https://www.reuters.com/world/europe/dispute-over-italian-coronavirus-study-shows-challenges-probing-origins-2021-07-23/